COYA has 36-month beta value of 0.26. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for COYA is 15.55M, and currently, short sellers hold a 1.68% ratio of that float. The average trading volume of COYA on July 04, 2025 was 60.46K shares.
COYA stock’s latest price update
Coya Therapeutics Inc (NASDAQ: COYA) has experienced a rise in its stock price by 3.11% compared to its previous closing price of $5.78. However, the company has seen a gain of 1.02% in its stock price over the last five trading days. businesswire.com reported 2025-06-18 that HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: https://www.
COYA’s Market Performance
COYA’s stock has risen by 1.02% in the past week, with a monthly rise of 5.49% and a quarterly drop of -8.87%. The volatility ratio for the week is 8.36% while the volatility levels for the last 30 days are 6.90% for Coya Therapeutics Inc The simple moving average for the past 20 days is 4.54% for COYA’s stock, with a -5.44% simple moving average for the past 200 days.
Analysts’ Opinion of COYA
Many brokerage firms have already submitted their reports for COYA stocks, with D. Boral Capital repeating the rating for COYA by listing it as a “Buy”. The predicted price for COYA in the upcoming period, according to D. Boral Capital is $15 based on the research report published on December 04, 2024 of the previous year 2024.
COYA Trading at 1.84% from the 50-Day Moving Average
After a stumble in the market that brought COYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.80% of loss for the given period.
Volatility was left at 6.90%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares surge +4.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.24% lower at present.
During the last 5 trading sessions, COYA rose by +1.02%, which changed the moving average for the period of 200-days by -6.88% in comparison to the 20-day moving average, which settled at $5.70. In addition, Coya Therapeutics Inc saw -2.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COYA starting from SNYDER DAVID S, who purchase 1,800 shares at the price of $7.19 back on Nov 14 ’24. After this action, SNYDER DAVID S now owns 8,800 shares of Coya Therapeutics Inc, valued at $12,934 using the latest closing price.
Swaminathan Arun, the Chief Executive Officer of Coya Therapeutics Inc, purchase 5,000 shares at $7.36 during a trade that took place back on Nov 13 ’24, which means that Swaminathan Arun is holding 10,000 shares at $36,797 based on the most recent closing price.
Stock Fundamentals for COYA
Current profitability levels for the company are sitting at:
- -5.28% for the present operating margin
- 1.0% for the gross margin
The net margin for Coya Therapeutics Inc stands at -4.65%. The total capital return value is set at -0.0%. Equity return is now at value -52.00%, with -45.12% for asset returns.
Currently, EBITDA for the company is -17.22 million with net debt to EBITDA at 1829.94. When we switch over and look at the enterprise to sales, we see a ratio of -9614.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.84.
Conclusion
To put it simply, Coya Therapeutics Inc (COYA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
